Search
Search Results
-
Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial
BackgroundDurvalumab plus gemcitabine and cisplatin has a significant clinical benefit for advanced biliary tract cancer (BTC). However, the high...
-
The Challenges of Outcomes-Based Contract Implementation for Medicines in Europe
ObjectivesThe aim was to outline the challenges of implementing outcomes-based contracts (OBCs) in Europe.
MethodsA sco** review was conducted,...
-
Value for Money of CAR-T Cell Therapy for Patients with Diffuse Large B-cell Lymphoma in China: Evidence from a Cost-Effectiveness Analysis
ObjectiveThis research assesses the cost effectiveness of Axicabtagene ciloleucel (Axi-cel), Tisagenlecleucel (Tis-cel), Relmacabtagene autoleucel...
-
Parent-Based Prevention of Bullying and Cyberbullying During COVID-19 Social Distancing: A Pilot Intervention using the MOST Framework
Parenting skills are important protective factors in the prevention of bullying and cyberbullying, yet few parent-based interventions have been...
-
A budget impact analysis of bezlotoxumab versus standard of care antibiotics only in patients at high risk of CDI recurrence from a hospital management perspective in Germany
BackgroundClostridioides difficile infection (CDI) is one of the leading nosocomial infections, resulting in increased hospital length of stay and...
-
Economic Evaluation of Evusheld for Preexposure Prevention of COVID-19 in High-Risk Populations: Early Evidence from Thailand
Background and AimsThe introduction of Coronavirus disease 2019 (COVID-19) vaccines urged all Thais to seek prevention of serious illness and death...
-
Assessing social preferences in reimbursement negotiations for new Pharmaceuticals in Oncology: an experimental design to analyse willingness to pay and willingness to accept
BackgroundPrice negotiations for specialty pharmaceuticals take place in a complex market setting. The determination of the added value of new...
-
Predictors of negotiated prices for new drugs in Germany
IntroductionIn Germany, all new, innovative medicines are subject to an early benefit assessment by the German Federal Joint Committee with...
-
A multicriteria decision analysis (MCDA) tool to purchase implantable medical devices in Egypt
BackgroundWith the availability of several similar medical devices performing the same function, choosing one for reimbursement is not easy,...
-
The three-year evolution of Germany’s Digital Therapeutics reimbursement program and its path forward
The 2019 German Digital Healthcare Act introduced the Digital Health Application program, known in German as ‘Digitale Gesundheitsanwendungen’...
-
Pricing, Procurement and Reimbursement Policies for Incentivizing Market Entry of Novel Antibiotics and Diagnostics: Learnings from 10 Countries Globally
BackgroundFostering market entry of novel antibiotics and enhanced use of diagnostics to improve the quality of antibiotic prescribing are avenues to...
-
Impact of COVID-19 on women living with HIV who are survivors of intimate partner violence
BackgroundWomen living with HIV (WLWH) experience higher rates of intimate partner violence (IPV) compared to women without HIV, but there has been...
-
Cost-effectiveness of toripalimab plus chemotherapy for advanced esophageal squamous cell carcinoma
BackgroundToripalimab is an immune checkpoint inhibitor (ICI) against programmed death ligand 1 (PD-L1). It has been approved for advanced esophageal...
-
Similarities and Differences in Health Technology Assessment Systems and Implications for Coverage Decisions: Evidence from 32 Countries
Health technology assessment (HTA) systems across countries vary in the way they are set up, according to their role and based on how funding...
-
Economic Evaluation of Sintilimab Plus Bevacizumab Versus Sorafenib as a First-line Treatment for Unresectable Hepatocellular Carcinoma
IntroductionThis study aimed to evaluate the cost-effectiveness of sintilimab plus bevacizumab versus sorafenib as a first-line treatment for...
-
Review and Assessment of Policy Options for Improving Access to Combination Therapies in Oncology in Europe
ObjectivesCombinations of on-patent therapies (CTs) are increasingly common in oncology. They cause challenges for funding and affordability, and...
-
Medicare Part D Coverage of Anti-obesity Medications: a Call for Forward-Looking Policy Reform
When the Medicare Part D benefit was constructed, drugs for weight loss were explicitly excluded from coverage, as the limited effectiveness and...